Cartesian reports durable responses in MG retreatment data
Cartesian Therapeutics announced deep and durable responses in a five-patient retreatment study of Descartes-08 for myasthenia gravis. The data supports the company's Phase 3 AURORA program, with data expected in 1Q27.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed